Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NRIX
NURIX THERAPEUTICS, INC.
NASDAQ
$26.21
▼ DOWN 2.47% (-0.67)

KEY STATISTICS

Market Cap$2.72 B
52w High$28.23
52w Low$8.20
Dividend Yield—
Frequency—
P/E-7.60
Volume908.26K
Shares Out.103.78M

COMPANY

LEADERSHIP

Arthur T. Sands
CHIEF EXECUTIVE
Arthur T. Sands

COMPENSATION 2026

Salary$674,584
Stock Awards$0
Incentive Plan Pay$510,000
All Other Comp.$23,358
Total$6,374,138

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 24, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
317

PRICE TARGET

Target High$45.00
Target Low$28.00
Target Median$34.00
Target Consensus$34.67

UPCOMING EARNINGS

DateOct 8, 2026
DayThursday
Rev. Est.$22.53M
OCT
8
THU

PRICE

$26.21 ▼ DOWN 2.47% (−$0.67)
$26.20$26.40$26.60$26.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM26.21

About Nurix Therapeutics, Inc.

https://www.nurixtx.com ↗

Nurix Therapeutics develops small molecule therapies, including BTK degraders and CBL-B inhibitors, for cancer and immune disorders, with collaborations involving Gilead and Sanofi.

INDUSTRY

Biotechnology

A PRODUCT NURIX THERAPEUTICS, INC. IS KNOWN FOR

Bexobrutideg (NX-5948)
Bexobrutideg (NX-5948)

Bexobrutideg is Nurix's oral small molecule BTK degrader in Phase 2 trials for relapsed/refractory CLL, representing the company's lead asset and most advanced candidate for potential regulatory approval.

COMPETITORS

COMPETITOR
ARVN COMPARE
CCCC COMPARE
KYMR COMPARE
LLY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Collaboration Revenue$7.89M $32.03M ▲$6.25M ▼$9.04M ▲
License Revenue— $0 — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
138
LISTED HERE
23
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.3M
XBI
0.59% · 2.6M
IWM
0.08% · 2.5M
ARKG
2.25% · 1.8M
SCHA
0.05% · 460.4K
DFAS
0.05% · 312.3K
FYC
0.43% · 230.4K
FESM
0.09% · 227.8K
PRFZ
0.11% · 114.0K
LABU
0.40% · 95.3K
XRSG.L
0.08% · 87.7K
RSSL
0.08% · 45.8K
BBC
0.95% · 18.5K
GSSC
0.03% · 11.8K
TILT
0.01% · 8.9K
ETLZ.DE
0.10% · 8.5K
RFLR
0.14% · 5.1K
URTY
0.03% · 3.9K
ADDS
1.31% · 3.4K
VETS
0.12% · 2.3K
TNXT
0.14% · 953
USFMDN.MX
0.00% · 310
RESM
0.08% · 191

INSTITUTIONAL OWNERSHIP

SHARES OWNED
80.90%
HOLDERS
287
TOP 12 OF 287 · RANKED BY POSITION SIZE
Blackrock, Inc.
8.9M sh · $138.35M
Fmr LLC
8.9M sh · $82.12M
Redmile Group, LLC
8.1M sh · $153.54M
Vestal Point Capital, LP
8.1M sh · $195.29M
Deep Track Capital, LP
7.7M sh · $187.69M
Rubric Capital Management LP
7.2M sh · $175.35M
Blackrock Inc.
6.8M sh · $142.33M
Svennilson Peter
6.8M sh · $235.85M
Vanguard Group Inc
5.9M sh · $112.86M
Price T Rowe Associates Inc /Md/
5.4M sh · $131.89M
State Street Corp
5.1M sh · $79.69M
Morgan Stanley
4.9M sh · $76.45M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hansen Gwenn
Purchase · 4.4K shares
2026-08-05
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hansen Gwenn
Sale · 4.4K shares
2026-08-05
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hansen Gwenn
Sale · 1.5K shares
2026-08-04
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hansen Gwenn
Sale · 2.6K shares
2026-08-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OUTPERFORM 4
OVERWEIGHT 3
14 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM Needham BUY Morgan Stanley OVERWEIGHT UBS BUY Mizuho OUTPERFORM BTIG BUY HC Wainwright & Co. BUY Stifel BUY

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
FTRE$18.81COMPARE
SEPN$38.91COMPARE
KURA$12.66COMPARE
PHAT$9.18COMPARE